


Appl. No. 10/632,187  
 Amdt. Dated May 3, 2005  
 Reply to Non-Final Office Action of November 3, 2004  
 Page 2 of 13

This listing of claims will replace all prior versions, and listings, of claims in the application:


LISTING OF CLAIMS:

Claim 1 (amended): The method of using of alkylphosphocholines of the general Formula I and/or

II:



Formula I



Formula II

in which, independently of one another,

n, m, p, z is a whole number between 0 and 4;

x is O, S, NH;


R is hydrogen, a linear or branched C<sub>1</sub> to C<sub>20</sub> alkyl group, which may be saturated or unsaturated with one to three double and/or triple bonds and unsubstituted or optionally substituted at the same or at different carbon atoms with one, two or more halogen, nitro, cyano, hydroxy, C<sub>1</sub> to C<sub>6</sub> alkoxy, amino, mono-(C<sub>1</sub> to C<sub>4</sub>) alkylamino or di-(C<sub>1</sub> to C<sub>4</sub>) alkylamino groups;

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> independently of one another represent hydrogen, a linear or branched (C<sub>1</sub> to C<sub>6</sub>) alkyl group, preferably methyl and ethyl, a (C<sub>3</sub> to C<sub>10</sub>) cycloalkyl group, which may be unsubstituted or optionally substituted at the same

Appl. No. 10/632,187  
 Amdt. Dated May 3, 2005  
 Reply to Non-Final Office Action of November 3, 2004  
 Page 3 of 13

or different carbon atoms with one, two or more halogen, nitro, cyano, hydroxy, C<sub>1</sub> to C<sub>6</sub> alkoxy, amino, mono-(C<sub>1</sub> to C<sub>4</sub>) alkylamino or di-(C<sub>1</sub> to C<sub>4</sub>) alkylaminogroups and pharmaceutically acceptable salts and prodrugs thereof; for the manufacture of a drug product for the treatment of benign and malignant oncos before and/or during treatment with an approved antitumor medicament antitumor or substance chosen from cis-platinum, carboplatinum, oxaliplatin, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabine and cytarabin and pharmaceutically acceptable salts and prodrugs thereof.

Claim 2 (amended): The method of using of compound having the structure of Formula I:



Formula I

where, independently of one another,

n is the integer 1 or 2;

m is the integer 1;

x is O;


R is H or a straight-chain or branched (C<sub>1</sub>-C<sub>17</sub>)-alkyl group which may be saturated or unsaturated with one to three double and/or triple bonds;

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> are, independently of one another, H or a straight-chain or branched (C<sub>1</sub>-C<sub>7</sub>)-alkyl group, preferably methyl and ethyl, a (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl group;

Appl. No. 10/632,187  
 Amdt. Dated May 3, 2005  
 Reply to Non-Final Office Action of November 3, 2004  
 Page 4 of 13

for the manufacture of a drug product for the treatment of benign and malignant oncosis before and/or during treatment with an approved antitumor medicament antitum or substance chosen from cis-platinum, carboplatinum, oxaliplatin, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabine and cytarabin.

Claim 3 (amended): The method of using of alkylphosphocholines of the general Formula II as claimed in claim 1



Formula II

where, independently of one another,

m, p are the integer 1;

n, z are the integer 2;

x is O;

R is H or a straight-chain or branched ( $\text{C}_1\text{-C}_{17}$ )-alkyl group which may be saturated or unsaturated with one to three double and/or triple bonds;

$\text{R}_1, \text{R}_2, \text{R}_3$  are, independently of one another, H or a straight-chain or branched ( $\text{C}_1\text{-C}_7$ )-alkyl group, preferably methyl and ethyl, a ( $\text{C}_3\text{-C}_7$ )-cycloalkyl group;

Appl. No. 10/632,187  
Amdt. Dated May 3, 2005  
Reply to Non-Final Office Action of November 3, 2004  
Page 5 of 13

for the manufacture of a drug product for the treatment of benign and malignant oncoses before and/or during treatment with an approved ~~antitumor medicament~~ antitumor or substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabine and cytarabin.

Claim 4 (amended): The method of using of octadecyl 1,1-dimethylpiperidinium-4-yl phosphate as claimed in claim 1 for the manufacture of a drug product for the treatment of benign and malignant oncoses before and/or during treatment with an approved ~~antitumor medicament~~ antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabine and cytarabin.

Claim 5 (amended): The method of using of alkylphosphocholines of the general formula Formula I and/or II as claimed in claims 1 to 4, where as in any one of the preceding claims, in which the approved antitumor medicaments may be alkylating agents, antimetabolites, plant alkaloids, platinum compounds, tumor antibiotics and agonists or antagonists of natural hormones.

Claim 6 (original): The method of using as claimed in claim 5, wherein the antitumor medicaments may be cisplatin, cyclophosphamide or Adriamycin.

Claim 7 (amended): The method of using of alkylphosphocholines of the general Formula I and/or II as claimed in claims 1 to 4, where as in any one of claims 1, 2, 3, and 4, in which the approved

Appl. No. 10/632,187  
Amdt. Dated May 3, 2005  
Reply to Non-Final Office Action of November 3, 2004  
Page 6 of 13

antitumor medicaments may be inhibitors of signal transduction in the form of high and low molecular weight inhibitors of receptor and/or cytosolic kinases.

Claim 8 (original): The method of using as claimed in claim 7, where the inhibitors may be monoclonal antibodies or heterocyclic compounds.

Claim 9 (amended): The method of using of alkylphosphocholines of the general Formula I and/or II as claimed in claims 1 to 8 any one of the preceding claims in a therapeutic dose which is effective for the treatment before and/or during the treatment with an approved antitumor medicament antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabine and cytarabine.

Claim 10 (amended): The method of using of alkylphosphocholines of the general formula Formula Ia I and/or II as claimed in claims 1 to 9 any one of the preceding claims, where the approved antitumor medicament is a combination of various cytostatics.

Claim 11 (amended): The method of using of alkylphosphocholines of the formula Formula I and/or II as claimed in claims 1 to 4 any one of claims 1, 2, 3, and 4 for the manufacture of a drug product for the treatment of benign and malignant oncoses before and/or during the treatment with an approved antitumor medicament antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabine and cytarabine.

Appl. No. 10/632,187  
Amtd. Dated May 3, 2005  
Reply to Non-Final Office Action of November 3, 2004  
Page 7 of 13

fludarabin, gemcitabine and cytarabine, wherein the drug product comprises the customary pharmaceutical carriers, excipients and/or diluents in addition to the alkylphosphocholine of the Formula I and or II.

Claim 12 (amended): A drug product comprising at least one alkylphosphocholine of the general Formula I and or II as in claim 1 and, where appropriate, carriers and/or excipients for use in the treatment of benign and malignant oncoses before and/or during the treatment with an approved ~~antitumor medicament~~ antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabine and cytarabine.